Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

White House regulatory reform agenda

This article was originally published in The Gray Sheet

Executive Summary

Office of Management and Budget is taking nominations for regs and guidance documents that impose "especially large burdens on small businesses and other small entities without an adequate benefit justification" for review. Issued March 18, 1OMB's draft report to Congress on the costs and benefits of federal regulations carries a 60-day comment period. HHS Secretary Thompson recently established a department-wide advisory panel on regulatory reform, set to meet March 20-21 in Phoenix. That panel is independently seeking comments on burdensome regulations (2"The Gray Sheet" March 18, 2002, p. 14). OMB also states that a "scientific advisory panel" including health and medical science experts will meet twice a year to evaluate Office of Information and Regulatory Affairs activities...

You may also be interested in...



Blood Safety Authority Shift To CDRH Opposed By Blood Centers

Legislation shifting responsibility for the regulation of blood safety screening tests from FDA's Center for Biologics Evaluation and Research to the device center puts an enormous burden on blood organizations, according to America's Blood Centers (ABC)

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.

UsernamePublicRestriction

Register

MT016314

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel